Last updated on March 2020

A Study Comparing Nivolumab Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

Brief description of study

The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced partial or entire removal of a kidney

Detailed Study Description

The study has two primary endpoints. The first primary completion date is anticipated to be reached Aug 2022 (DFS in Part A). The second primary completion date is anticipated to be reached July 2024 (DFS in Part B).

Clinical Study Identifier: NCT03138512

Find a site near you

Start Over

Local Institution

Arakawa-ku, Japan
  Connect »

Local Institution

Bunkyo-ku, Japan
  Connect »

Local Institution

Shinjuku-Ku, Japan
  Connect »